Open AccessThe Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines
Author(s) -
Anandita Agarwala,
Jing Liu,
Christie M. Ballantyne,
Salim S. Virani
Publication year - 2019
Publication title -
current cardiovascular risk reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.285
H-Index - 27
eISSN - 1932-9563
pISSN - 1932-9520
DOI - 10.1007/s12170-019-0616-y
Subject(s) - medicine , atherosclerotic cardiovascular disease , ezetimibe , ldl cholesterol , cholesterol , disease
In 2018, the AHA/ACC multi-society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind each of the risk- enhancing factors to help clinicians perform a more personalized cardiovascular risk assessment.